Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Castrate- Resistant Prostate Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06059118
What this trial is testing

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 50
Early research (Phase 1)Study completedNCT04179396
What this trial is testing

Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
pharmaand GmbH 8
Testing effectiveness (Phase 2)Active Not RecruitingNCT06383052
What this trial is testing

177Lu-NYM032 Injection in mCRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Norroy Bioscience Co., LTD 30
Testing effectiveness (Phase 2)Study completedNCT01074138
What this trial is testing

Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer

Who this might be right for
Bone-Metastatic, Castration-Resistant Prostate Cancer
Athenex, Inc. 31
Early research (Phase 1)Active Not RecruitingNCT05245006
What this trial is testing

PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate Cancer
Robert Flavell, MD, PhD 30
Not applicableLooking for participantsNCT07050433
What this trial is testing

COMPASS Study for Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Duke University 48
Testing effectiveness (Phase 2)WithdrawnNCT02966587
What this trial is testing

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Who this might be right for
Castration Levels of TestosteroneHormone-Resistant Prostate CancerMicrosatellite Instability
University of Washington
Post-approval studies (Phase 4)UnknownNCT03432949
What this trial is testing

Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPC

Who this might be right for
Metastatic Prostate Cancer
University Health Network, Toronto 24
Testing effectiveness (Phase 2)Ended earlyNCT05489991
What this trial is testing

TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Tceleron Therapeutics, Inc. 1
Testing effectiveness (Phase 2)Looking for participantsNCT06610825
What this trial is testing

Castrate Resistant Prostate Cancer Enhertu Therapy

Who this might be right for
Prostate Cancer MetastaticProstate CancerCRPC
Washington D.C. Veterans Affairs Medical Center 60
Testing effectiveness (Phase 2)Looking for participantsNCT05563558
What this trial is testing

Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)

Who this might be right for
Prostate Cancer Metastatic
Fundacion Oncosur 42
Testing effectiveness (Phase 2)Looking for participantsNCT04868604
What this trial is testing

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

Who this might be right for
Prostatic Neoplasms, Castration-Resistant
Clarity Pharmaceuticals Ltd 54
Early research (Phase 1)Study completedNCT03778047
What this trial is testing

A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch

Who this might be right for
Metastatic Castration Resistant Prostate Cancer
Hinova Pharmaceuticals Inc. 10
Large-scale testing (Phase 3)Not Yet RecruitingNCT07641855
What this trial is testing

BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer

Who this might be right for
Castration-resistant Prostate Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 180
Not applicableStudy completedNCT03896984
What this trial is testing

Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Bayer 346
Not applicableUnknownNCT03786848
What this trial is testing

Personalized Mini-PDX for Metastatic CRPC

Who this might be right for
Prostate Cancer
Tianjin Medical University Second Hospital 15
Testing effectiveness (Phase 2)Study completedNCT01511536
What this trial is testing

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Sanofi 38
Not applicableEnded earlyNCT02491411
What this trial is testing

Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel

Who this might be right for
Hormone-Resistant Prostate CancerMetastatic Prostate CarcinomaProstate Adenocarcinoma+1 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 5
Testing effectiveness (Phase 2)Study completedNCT02463799
What this trial is testing

Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC

Who this might be right for
Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 36
Not applicableNo Longer AvailableNCT01834209
What this trial is testing

Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Neoplasms
Janssen Research & Development, LLC
Next Page